Omnicom Media Retains Bristol Myers Squibb Account
Omnicom Media keeps Bristol Myers Squibb's US media business and takes on additional healthcare professional media work after a competitive review.
Updated on Nov. 20, 2026 in Healthcare

Omnicom Media retained Bristol Myers Squibb's US media account following a competitive review and secured additional healthcare professional media responsibilities. The business had previously been handled by IPG Mediabrands, which Omnicom acquired.
Why it matters
The retention shifts a significant pharmaceutical media budget within the healthcare advertising sector and consolidates a large account under Omnicom. It follows Omnicom's earlier win of Novo Nordisk's US media buying business from WPP.
Bristol Myers Squibb's media budget stood at approximately $430 million in 2023, according to a request for information issued during a prior review. Novo Nordisk's annual media expenditure exceeds $600 million, though the source does not state the value of the Omnicom contract.
The players
Omnicom
Omnicom is a major global advertising and marketing holding company headquartered in New York that owns several agency networks.
Bristol Myers Squibb
Bristol Myers Squibb is a large American pharmaceutical company that develops and markets prescription medicines across multiple therapeutic areas.
Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company best known for its diabetes and obesity medicines, including semaglutide.
WPP
WPP is a British multinational advertising and public relations company that operates several agency brands worldwide.
The details
Omnicom Media kept Bristol Myers Squibb's US media account after a competitive review and took on added healthcare professional media responsibilities that had been handled by WPP-owned CMI Media Group. The account had moved to IPG Mediabrands in 2023 from Havas, and Omnicom's acquisition of Interpublic Group brought it under the Omnicom umbrella.
Timeline
2023: IPG Mediabrands secured Bristol Myers Squibb's US media business from Havas.
Earlier this year: Novo Nordisk awarded its US media buying business to Omnicom, moving it from WPP.
2027: The expanded Bristol Myers Squibb mandate takes effect.
Market Landscape
The retention follows Omnicom's acquisition of Interpublic Group, which folded the former IPG Mediabrands accounts into the Omnicom network. It also comes alongside Omnicom's earlier win of Novo Nordisk's media buying business from WPP, marking two significant pharmaceutical media accounts moving between major holding companies in the same period.
For consumers, changes in pharmaceutical media agency relationships rarely affect drug prices or availability directly. The shifts mainly influence how drug manufacturers allocate advertising budgets across television, digital, and professional channels.
The takeaway
Agency consolidation in healthcare advertising can concentrate large pharmaceutical budgets among a few holding companies. Readers following drug marketing can track these account moves to understand where advertising spending is directed.
What happens next
The expanded Bristol Myers Squibb healthcare professional media mandate is scheduled to take effect in 2027.
Further reading
For more on pharmaceutical marketing, explore Healthcare coverage on Wisevoter.
Source note: This article includes information reported by Indian Advertising Media & Marketing News - exchange4media.






